0
Letters |

A Word From Our ModeratorA Word From Our Moderator

JAMA. 2007;297(2):156-157. doi:10.1001/jama.297.2.156-a
Text Size: A A A
Published online

AUTHOR INFORMATION

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

A WORD FROM OUR MODERATOR

To the Editor: In their Commentary, Dr Kraemer and colleagues1 draw attention to the importance of moderators of treatment outcomes, the often unsatisfactory way these are dealt with (if at all) in randomized clinical trials (RCTs), and the potentially serious consequences of this neglect on patient care. They propose that every RCT should include a search for putative moderators of treatment outcome. Although acknowledging that positive results of such analyses rarely provide proof of the existence of these moderators, they stress that the importance resides in the hypotheses that the analyses generate. These hypotheses can then be tested in subsequent adequately powered and populated RCTs. However, it may take years to design, acquire adequate funding for, and execute such an RCT.

As an alternative, conducting N-of-1 trials2 can be valuable to further investigate information on moderators of treatment outcome. As a hypothetical example, suppose an RCT had been conducted to test the efficacy of drug treatment of primary Raynaud phenomenon, that no overall benefit of the drug had been found, but analysis of putative moderators of treatment outcome had suggested that women might respond favorably, although this result was not statistically significant. Women with Raynaud phenomenon could then be included in N-of-1 trials, in which they would be treated in a double-blind crossover design with multiple treatment pairs with either the drug or a placebo in random order.2 The presence or absence of differences in symptom scores during treatment would then prove or disprove the effectiveness of this drug for the patient.

Pooling the results of all of these N-of-1 trials may substantiate that sex is a moderator of treatment outcome.3 Moreover, comparison of responders and nonresponders in these N-of-1 trials may be used to identify additional moderators of treatment outcome. This approach may obviate the need for RCTs, which would be a great boon in the case of rare chronic diseases. It has an additional advantage in that daily patient care can be integrated with clinical research.

N-of-1 trials have their own limitations. They are not applicable to surgical or acute medical conditions. However, for chronic medical conditions, they may be invaluable in the quest for “tailored therapy,” one of the holy grails of clinical medicine.

Financial Disclosures: None reported.

References
Kraemer HC, Frank E, Kupfer DJ. Moderators of treatment outcomes: clinical, research, and policy importance.  JAMA. 2006;2961286-1289
PubMed
Guyatt G, Sackett D, Adachi J.  et al.  A clinician's guide for conducting randomized trials in individual patients.  CMAJ. 1988;139497-503
PubMed
Zucker DR, Schmid CH, McIntosh MW, D'Agostino RB, Selker HP, Lau J. Combining single patient (N-of-1) trials to estimate population treatment effects and to evaluate individual patient responses to treatment.  J Clin Epidemiol. 1997;50401-410
PubMed

First Page Preview

First page PDF preview

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

Kraemer HC, Frank E, Kupfer DJ. Moderators of treatment outcomes: clinical, research, and policy importance.  JAMA. 2006;2961286-1289
PubMed
Guyatt G, Sackett D, Adachi J.  et al.  A clinician's guide for conducting randomized trials in individual patients.  CMAJ. 1988;139497-503
PubMed
Zucker DR, Schmid CH, McIntosh MW, D'Agostino RB, Selker HP, Lau J. Combining single patient (N-of-1) trials to estimate population treatment effects and to evaluate individual patient responses to treatment.  J Clin Epidemiol. 1997;50401-410
PubMed
CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.